Rein Therapeutics (NASDAQ:RNTX) Now Covered by Maxim Group

Equities research analysts at Maxim Group assumed coverage on shares of Rein Therapeutics (NASDAQ:RNTX) in a research note issued to investors on Monday,Benzinga reports. The firm set a “buy” rating and a $4.00 price target on the stock. Maxim Group’s price target would suggest a potential upside of 365.12% from the company’s previous close.

Several other analysts also recently commented on RNTX. HC Wainwright dropped their price objective on Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Wall Street Zen raised Rein Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, Weiss Ratings lowered Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $6.00.

Rein Therapeutics Stock Performance

NASDAQ:RNTX traded down $0.00 during trading hours on Monday, hitting $0.86. The stock had a trading volume of 454,278 shares, compared to its average volume of 432,924. Rein Therapeutics has a one year low of $0.83 and a one year high of $2.18. The company has a market cap of $73.56 million, a price-to-earnings ratio of -0.45 and a beta of 1.35. The business’s 50 day moving average is $0.99 and its 200-day moving average is $1.20.

Rein Therapeutics (NASDAQ:RNTX) last posted its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.30. On average, sell-side analysts anticipate that Rein Therapeutics will post -0.53 EPS for the current fiscal year.

Institutional Trading of Rein Therapeutics

A number of institutional investors have recently modified their holdings of RNTX. Geode Capital Management LLC acquired a new position in Rein Therapeutics during the 2nd quarter worth approximately $344,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Rein Therapeutics in the second quarter valued at approximately $68,000. Cable Car Capital LP acquired a new stake in shares of Rein Therapeutics in the second quarter valued at approximately $588,000. Vanguard Group Inc. lifted its position in shares of Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock worth $1,338,000 after purchasing an additional 284,300 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new stake in shares of Rein Therapeutics in the third quarter worth $35,000. 90.89% of the stock is currently owned by institutional investors.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.